Apollo Endosurgery (Apollo Endosurgery) EV-to-Revenue : 7.54 (As of May. 13, 2024)

View and export this data going back to 2007. Start your Free Trial

What is Apollo Endosurgery EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Apollo Endosurgery's enterprise value is $579.78 Mil. Apollo Endosurgery's Revenue for the trailing twelve months (TTM) ended in Dec. 2022 was $76.86 Mil. Therefore, Apollo Endosurgery's EV-to-Revenue for today is 7.54.

The historical rank and industry rank for Apollo Endosurgery's EV-to-Revenue or its related term are showing as below:

APEN' s EV-to-Revenue Range Over the Past 10 Years
Min: -5.46 Med: 2.78 Max: 120.13
Current: 7.54

During the past 13 years, the highest EV-to-Revenue of Apollo Endosurgery was 120.13. The lowest was -5.46. And the median was 2.78.

APEN's EV-to-Revenue is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 3.265 vs APEN: 7.54

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-13), Apollo Endosurgery's stock price is $10.00. Apollo Endosurgery's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2022 was $1.89. Therefore, Apollo Endosurgery's PS Ratio for today is 5.30.

Apollo Endosurgery EV-to-Revenue Historical Data

The historical data trend for Apollo Endosurgery's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollo Endosurgery EV-to-Revenue Chart

Apollo Endosurgery Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EV-to-Revenue

Get a 7-Day Free Trial

1.20

1.65

2.60

4.70

5.45

Apollo Endosurgery Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
EV-to-Revenue	Get a 7-Day Free Trial															4.70	3.26	1.85	3.02	5.45

Competitive Comparison of Apollo Endosurgery's EV-to-Revenue

For the Medical Devices subindustry, Apollo Endosurgery's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Apollo Endosurgery's EV-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Apollo Endosurgery's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Apollo Endosurgery's EV-to-Revenue falls into.

Apollo Endosurgery EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Apollo Endosurgery's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	579.782	/	76.856
	=	7.54

Apollo Endosurgery's current Enterprise Value is $579.78 Mil.
Apollo Endosurgery's Revenue for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $76.86 Mil.

Apollo Endosurgery (NAS:APEN) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Apollo Endosurgery's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	10.00	/	1.888
	=	5.30

Apollo Endosurgery's share price for today is $10.00.
Apollo Endosurgery's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.89.

Apollo Endosurgery EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Apollo Endosurgery's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Apollo Endosurgery (Apollo Endosurgery) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Apollo Endosurgery Inc (NAS:APEN) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

1120 S. Capital of Texas Highway, Building 1, Suite 300, Austin, TX, USA, 78746

Website

https://www.apolloendo.com

Apollo Endosurgery Inc is active in the healthcare sector based in the United States. As a developer of medical devices, Apollo focuses on addressing obesity, as well as other gastrointestinal disorders. Its products are used by general surgeons, bariatric surgeons and gastroenterologists in a variety of settings to provide interventional therapy to patients who suffer from obesity. The company's products include the OverStitch Endoscopic Suturing System, X-Tack Endoscopic HeliX Tacking System, and the Orbera Intragastric Balloon System.

Executives

Antal Rohit Desai	10 percent owner	C/O PROCEPT BIOROBOTICS CORPORATION, 900 ISLAND DRIVE, REDWOOD CITY CA 94065
Sharon O'keefe	director	C/O VOCERA COMMUNICATIONS, INC., 525 RACE STREET, SAN JOSE CA 95126
Jeannette Bankes	director	ONE ALLENTOWN PARKWAY, ONE ALLENTOWN PARKWAY, ALLEN TX 75002
Jeffrey G. Black	officer: Chief Financial Officer	4955 DIRECTORS PLACE, SAN DIEGO CA 92121
Mike Gutteridge	officer: VP, Int'l Sales and Marketing	1120 S. CAPITAL OF TEXAS HIGHWAY, BUILDING 1, SUITE #300, AUSTIN TX 78746
Cpmg Inc	10 percent owner	4215 WEST LOVERS LANE, SUITE 100, DALLAS TX 75209
Mcgaughy R Kent Jr	director, 10 percent owner	500 CRESCENT COURT, SUITE 250, DALLAS TX 75201
Chas Mckhann	director, officer: President and CEO	1555 ADAMS DRIVE, C/O INTERSECT ENT, INC., MENLO PARK CA 94025
David Pacitti	director	C/O APOLLO ENDOSURGERY, INC., 1120 S., CAPITAL OF TEXAS HWY, BLDG. 1, SUITE 300, AUSTIN TX 78746
John R Barr	director	VI TECHNOLOGIES INC, 134 COOLIDGE AVENUE, WATERTOWN MA 02472
Neil Gagnon	10 percent owner	1370 AVENUE OF THE AMERICAS, 24TH FLOOR, NEW YORK NY 10019
Traweek James W Jr	10 percent owner	2000 MCKINNEY AVE, SUITE 2125, DALLAS TX 75201
Todd Newton	director, officer: Chief Executive Officer	1120 S CAPITAL OF TX HWY, BUILDING ONE, STE 300, AUSTIN TX 78746
Stonepine Capital, L.p.	10 percent owner	919 NW BOND STREET, SUITE 204, BEND OR 97703
Matthew S Crawford	director, 10 percent owner	3600 N CAPITAL OF TEXAS HWY, SUITE B180, AUSTIN TX 78746